Saturday 17 October 2026
Export APRE’s income statement to Excel — free account
Aprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024. In the quarter to June 2026, revenue fell 98.4%, EPS grew 86.8% and free cash flow fell 5.22%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.58
0.04
−6.45%
Follow APRE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
19.32 | 19.45 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(2.97) | (1.88) | — | — | |
P/B ratio |
0.86 | 0.45 | — | — | |
Price to Tangible BV |
0.86 | 0.45 | — | — | |
EV/Sales |
(8.78) | (31.65) | — | — | |
EV/EBITDA |
0.31 | 0.68 | — | — | |
EV/Operating CF |
0.32 | 0.70 | — | — | |
EV/FCF |
0.32 | 0.70 | — | — | |
Quick Ratio |
5.12 | 5.28 | 8.77 | 13.33 | |
Current Ratio |
5.20 | 5.63 | 8.92 | 13.55 | |
Net Debt/EBITDA |
4.41 | 5.53 | 13.57 | 10.24 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.00 | 0.00 | |
Operating CF/Net income |
1.07 | 1.21 | 0.84 | 0.91 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (2.66) | |
Research and Development Expense of Revenue |
91,050.00% | 30,569.70% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
82,238.89% | 49,624.24% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6,316.67% | 3,303.03% | 0.00% | 0.00% | |
Graham Net Nets |
1.12 | 2.17 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(145.27%) | (232.94%) | — | — | |
Free Cash Flow Yield |
(142.70%) | (232.27%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.50) | (0.45) | (0.19) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.50) | (0.45) | (0.19) | (0.06) | |
Cash per Share |
2.15 | 2.23 | 3.16 | 0.77 | |
Shareholders Equity per Share |
1.71 | 1.90 | 2.83 | 0.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.71 | 1.90 | 2.83 | 0.72 | |
Free Cash Flow |
(3.17) | (2.96) | (2.76) | (3.29) | |
Working Capital |
11.26 | 12.80 | 41.95 | 38.82 | |
Capital Expenditures |
— | — | — | (0.02) | |
Net Current Asset Value |
10.54 | 12.07 | 41.22 | 38.09 | |
EV/EBIT |
0.31 | 0.68 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
0.90 | 1.03 | 2.11 | 1.07 | |
Average Assets |
20.61 | 19.96 | 33.92 | 29.80 | |
Average Common Equity |
16.43 | 15.87 | 28.57 | 25.94 |
Columns are period end dates